论文部分内容阅读
我们将138例结肠癌手术病例随机分成术后化疗组和单纯手术组,5年生存率术后化疗组为62.5％(30/48),单纯手术组为43.3％(39/90),二者差异有显著意义(P<0.05)。Duke′s D期病例,3年生存率术后化疗组为40.0％(4/10),单纯手术组为5.0％(1/20),二者差异有显著意义(P<0.05)。按行根治术病例及Duke′s A、B、C期病例分别单独分析中,3和5年生存率术后化疗组均比单纯手术组不同程度增高,但均P>0.05。本文认为,术后辅助化疗确能提高晚期结肠癌的长期生存率,但对早、中期远期疗效尚不能肯定,需从化疗方案,给药途径等方面进一步研究。
We randomly divided 138 cases of colon cancer surgery into postoperative chemotherapy and surgery alone. The 5-year survival rate was 62.5% (30/48) in the postoperative chemotherapy group and 43.3% (39/90) in the surgery alone group. The difference was significant (P < 0.05). In Duke’s D-stage cases, the 3-year survival rate was 40.0% (4/10) in the postoperative chemotherapy group and 5.0% (1/20) in the surgery alone group, with a significant difference (P<0.05). In the case of radical surgery and Duke’s A, B, and C stages, the 3- and 5-year survival rates in the postoperative chemotherapy group were higher than those in the surgery alone group, but all were P>0.05. This article believes that postoperative adjuvant chemotherapy can improve the long-term survival of advanced colon cancer, but the long-term efficacy of the early and mid-term is still not sure, need to be further studied from the chemotherapy regimen, the route of administration.